RINVOQ Drug Patent Profile

When do Rinvoq patents expire, and what generic alternatives are available?

Rinvoq is a drug marketed by Abbvie and is included in two NDAs. There are forty-four patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and seventeen patent family members in forty-one countries.

The generic ingredient in RINVOQ is upadacitinib. One supplier is listed for this compound. Additional details are available on the upadacitinib profile page.

DrugPatentWatch^® Generic Entry Outlook for Rinvoq

Rinvoq was eligible for patent challenges on August 16, 2023.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be October 17, 2036. This may change due to patent challenges or generic licensing.

There have been three patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There are two tentative approvals for the generic drug (upadacitinib), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for RINVOQ

International Patents:	217
US Patents:	44
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	46
Clinical Trials:	41
Patent Applications:	1,347
Drug Prices:	Drug price information for RINVOQ
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for RINVOQ
What excipients (inactive ingredients) are in RINVOQ?	RINVOQ excipients list
DailyMed Link:	RINVOQ at DailyMed

See drug prices for RINVOQ

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for RINVOQ

Constraining patent/regulatory exclusivity:

9,951,080

NDA:

211675

Dosage:

TABLET, EXTENDED RELEASE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for RINVOQ

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
AbbVie	PHASE3
Modern Biosciences Ltd	PHASE1
Berinstein, Jeffrey	Phase 4

See all RINVOQ clinical trials

Pharmacology for RINVOQ

Drug Class	Janus Kinase Inhibitor
Mechanism of Action	Janus Kinase Inhibitors

Paragraph IV (Patent) Challenges for RINVOQ

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
RINVOQ	Extended-release Tablets	upadacitinib	45 mg	211675	3	2023-08-16

US Patents and Regulatory Information for RINVOQ

RINVOQ is protected by sixty US patents and eight FDA Regulatory Exclusivities.

This potential generic entry date is based on patent 9,951,080.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	RINVOQ	upadacitinib	TABLET, EXTENDED RELEASE;ORAL	211675-002	Jan 14, 2022		RX	Yes	No	10,981,923			Y
Abbvie	RINVOQ	upadacitinib	TABLET, EXTENDED RELEASE;ORAL	211675-003	Mar 16, 2022		RX	Yes	Yes	11,198,697		Y
Abbvie	RINVOQ	upadacitinib	TABLET, EXTENDED RELEASE;ORAL	211675-001	Aug 16, 2019		RX	Yes	No	10,981,924		Y

EU/EMA Drug Approvals for RINVOQ

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
AbbVie Deutschland GmbH & Co. KG	Rinvoq	upadacitinib	EMEA/H/C/004760Rheumatoid arthritisRINVOQ is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). RINVOQ may be used as monotherapy or in combination with methotrexate.Psoriatic arthritisRINVOQ is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more DMARDs. RINVOQ may be used as monotherapy or in combination with methotrexate.Axial spondyloarthritisNon-radiographic axial spondyloarthritis (nr-axSpA)RINVOQ is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).Ankylosing spondylitis (AS, radiographic axial spondyloarthritis)RINVOQ is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy.Atopic dermatitisRINVOQ is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy.Ulcerative colitisRINVOQ is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent. Crohn’s diseaseRINVOQ is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.	Authorised	no	no	no	2019-12-16

International Patents for RINVOQ

When does loss-of-exclusivity occur for RINVOQ?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

European Patent Office

Hong Kong

Israel

Japan

Mexico

Russian Federation

Singapore

South Korea

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering RINVOQ around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	2021020902	（３Ｓ，４Ｒ）−３−エチル−４−（３Ｈ−イミダゾ［１，２−ａ］ピロロ［２，３−ｅ］−ピラジン−８−イル）−Ｎ−（２，２，２−トリフルオロエチル）ピロリジン−１−カルボキサミドおよびそれの固体型の製造方法 (PROCESSES FOR PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF)
Israel	220054
China	120957723	用乌帕替尼治疗儿科患者的方法

Supplementary Protection Certificates for RINVOQ

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2506716	723	Finland
2506716	C02506716/01	Switzerland		PRODUCT NAME: UPADACITINIB; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 67257 20.01.2020
2506716	122020000011	Germany		PRODUCT NAME: UPADACITINIB ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/19/1404 20191216

Market Dynamics and Financial Trajectory for RINVOQ

Last updated: November 17, 2025

Introduction

RINVOQ (upadacitinib) has emerged as a prominent player in the pharmaceutical landscape, primarily positioning itself within the treatment spectrum for autoimmune and inflammatory disorders. As a selective Janus kinase (JAK) inhibitor, RINVOQ addresses conditions such as rheumatoid arthritis (RA), atopic dermatitis, psoriatic arthritis, and ankylosing spondylitis. With its potential to reshape treatment paradigms, understanding its market dynamics and financial trajectory is critical for stakeholders, including investors, healthcare providers, and competitors.

This analysis synthesizes current trends, competitive forces, regulatory developments, and commercial strategies influencing RINVOQ's market performance, underscoring its growth potential and challenges.

Market Overview and Therapeutic Space

The autoimmune biologics and targeted synthetic therapies market has witnessed rapid expansion, driven by increasing prevalence of chronic inflammatory diseases and a paradigm shift towards personalized medicine. According to IQVIA, the global rheumatology market alone was estimated to reach approximately $30 billion in 2022, with JAK inhibitors constituting a significant and growing segment [1].

RINVOQ's positioning as an oral JAK inhibitor confers advantages over biologic therapies, notably patient compliance and rapid onset of action. Its approvals across multiple indications, including rheumatoid arthritis (FDA approved 2019), atopic dermatitis, psoriatic arthritis, ulcerative colitis (under review), and ankylosing spondylitis, diversify its revenue streams and market footprint.

Market Dynamics

1. Competitive Landscape

RINVOQ operates within a highly competitive environment featuring biologics (e.g., Humira, Enbrel, Stelara) and other JAK inhibitors such as Pfizer’s Xeljanz (tofacitinib) and AbbVie’s Rinvoq competitors [2]. The uniqueness of RINVOQ’s selectivity for JAK1 positions it as potentially more efficacy-oriented with a favorable safety profile, vital differentiators.

The entry of biosimilars for established biologics exerts downward pressure on prices, emphasizing the importance of RINVOQ’s oral delivery and expanding its appeal among patients and clinicians seeking alternatives.

2. Regulatory and Clinical Developments

Regulatory approvals across multiple geographies have bolstered RINVOQ's market access. Notably, the FDA approved RINVOQ for multiple indications, and subsequent approval in the EU and other markets broadened its reach. Ongoing clinical trials exploring additional indications such as Crohn’s disease and ulcerative colitis may further enhance its portfolio [3].

Clinical data demonstrating superior efficacy or improved safety over competing therapies can influence prescriber preferences. Conversely, safety concerns, especially regarding thromboembolic events and infections associated with JAK inhibitors, pose regulatory and commercial challenges [4].

3. Pricing and Reimbursement Strategies

Pricing remains pivotal; RINVOQ is positioned as a premium therapy, with pricing strategies reflecting its innovative mechanism and clinical benefits. Navigating reimbursement landscapes, particularly in cost-conscious markets, influences uptake. Value-based pricing models and tiered reimbursement frameworks are increasingly affecting access.

4. Market Penetration and Adoption

The rate of penetration into rheumatology and dermatology practices hinges on clinician familiarity, formulary inclusion, and patient acceptance. Educational initiatives and real-world evidence can accelerate adoption. The current COVID-19 pandemic has underscored telemedicine’s growing role, potentially facilitating patient engagement with oral therapies like RINVOQ.

5. Patent and Intellectual Property Considerations

Patent protection offers exclusivity, typically lasting until 2030s for key formulations. Patent litigations and licensing agreements remain instrumental for maintaining market dominance.

Financial Trajectory and Revenue Outlook

1. Current Revenue Landscape

Since its launch, RINVOQ has exhibited strong revenue growth. In 2022, AbbVie reported net revenues of approximately $74 billion, with the immunology segment representing a significant proportion, driven partly by RINVOQ and Humira [5].

In its most recent quarterly reports, RINVOQ sales have surpassed expectations in certain markets, reflecting strong prescription uptake. The drug’s contribution to AbbVie’s immunology revenues continues to ascend, with estimates indicating a compound annual growth rate (CAGR) exceeding 20% in the past three years.

2. Revenue Drivers

• Expanding indications: Each approved indication adds to revenue. The ongoing approval pipeline and expanding label claims forecast sustained growth.
• Geography expansion: Entry into new markets, particularly in emerging economies, broadens the revenue base.
• Pricing strategies: Stable or increasing pricing, aligned with value demonstration, sustains revenue streams.

3. Growth Forecasts

Industry analysts project RINVOQ’s global sales to reach approximately $4.5 to $6 billion by 2027—a CAGR around 18-22%—assuming successful indication expansion and robust market penetration [6].

Factors supporting this trajectory include:

• Increasing disease prevalence, especially RA and atopic dermatitis.
• Clinical evidence favoring RINVOQ over competitors.
• Strategic expansion into new therapeutic areas.

However, potential market saturation, safety concerns, and regulatory hurdles may temper growth expectations.

4. Risks and Challenges

Emerging competitors, patent expiry timelines, and scrutiny over safety signals could adversely influence revenue prospects. Moreover, pricing pressures in healthcare systems worldwide might constrain profit margins.

Future Outlook

RINVOQ’s financial trajectory appears promising, anchored by clinical efficacy, expanding indications, and strategic geographic expansion. The drug's strong positioning within the JAK inhibitor class, combined with AbbVie's robust commercialization infrastructure, suggests continued revenue growth.

The key growth catalysts will include successful approval of new indications, accumulation of real-world evidence supporting safety and efficacy, and effective market penetration strategies.

Conversely, the concurrent emergence of next-generation JAK inhibitors with differentiated profiles, and evolving regulatory landscapes, could influence RINVOQ’s long-term competitiveness.

Key Takeaways

• RINVOQ competes effectively by leveraging its oral administration, selectivity, and expanding indication portfolio.
• Clinical trial outcomes and safety profiles are central to prescriber confidence and market acceptance.
• Revenue growth anticipates high double-digit CAGR, driven by indication expansion and geographic penetration.
• Pricing strategies and reimbursement negotiations are critical to sustaining profitability amid healthcare cost containment pressures.
• Future success hinges on ongoing clinical development, regulatory approvals, and maintaining a competitive edge against emerging therapies.

FAQs

1. How does RINVOQ’s mechanism of action differ from other JAK inhibitors?
RINVOQ selectively inhibits JAK1, aiming to provide effective immunomodulation with potentially fewer side effects compared to non-selective JAK inhibitors like tofacitinib, which target multiple JAK isoforms [7].

2. What are the main safety concerns associated with RINVOQ?
Safety issues include risks of infections, blood clots, and changes in blood counts. Regulatory agencies have issued warnings requiring post-marketing surveillance to monitor thromboembolic events and other adverse effects [8].

3. Which indications are currently approved for RINVOQ?
As of 2023, RINVOQ holds approvals for rheumatoid arthritis, atopic dermatitis, psoriatic arthritis, and ankylosing spondylitis. Additional approvals, such as ulcerative colitis, are under review or pending [3].

4. What is the potential impact of biosimilars and generic biologics on RINVOQ’s market share?
While biosimilars threaten biologic therapies’ pricing, RINVOQ’s oral route and distinct mechanism may insulate it from direct competition. Nevertheless, price pressures and formulary priorities could influence its market share.

5. What are the prospects for RINVOQ’s expansion into new therapeutic areas?
Clinical trials are exploring RINVOQ for conditions like Crohn’s disease and vitiligo. Successful demonstration of efficacy and safety could unlock additional revenue streams, enhancing its market lifespan.

---

Sources
[1] IQVIA, Global Outlook for Rheumatology Market, 2022.
[2] Evaluate Pharma, JAK Inhibitors Market Report, 2022.
[3] AbbVie Press Releases, Approval Announcements, 2022-2023.
[4] FDA Safety Communications, 2021.
[5] AbbVie Annual Report, 2022.
[6] MarketWatch, RINVOQ Sales Forecast, 2023.
[7] The New England Journal of Medicine, JAK Inhibitors Comparative Review, 2021.
[8] EMA Pharmacovigilance Data, 2022.